In-Depth Patient Assessment for a COVID-19 Vaccine

Page last updated: 21 June 2021

The Australian Government is committed to offering every person in Australia access to safe and effective COVID-19 vaccines at no cost.

From 18 June 2021, the Government introduced two new MBS items (10660 and 10661) to support GPs and OMPs to provide in-depth clinical assessments of patients aged 50 years and over regarding patients’ individual health risks and benefits associated with receiving a COVID-19 vaccine.

MBS items 10660 and 10661 may only be claimed where a General Practitioner (GP) or Other Medical Practitioner (OMP) attends to a patient in person for more than 10 minutes, and must be provided in conjunction with a relevant MBS COVID-19 vaccine suitability assessment item (93624, 93625, 93626, 93627, 93634, 93635, 93636, 93637, 93644, 93645, 93646, 93647, 93653, 93654, 93655 and 93656).

Consistent with the other MBS vaccine suitability assessment items, items 10660 and 10661 must be bulk-billed

Note: Due to time constraints it has not been possible to amend the legislation that establishes 100% rebates for GPs and OMPs services. The rebate for these items is therefore paid at 85% of the item fee. The fee amount has been increased so that the medicare rebate paid for these items is at the same level as the equivalent rebate for a Level B consultation by a GP or OMP.

Further information is available in the following factsheet:

Last Updated 21 June 2021
PDF version Factsheet In depth consultation(PDF 232 KB)
Word version Factsheet In depth consultation (Word 48 KB)

In this section